BI 765845

DRUG4 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim

Conditions

HealthyMyocardial Infarctionacute myocardial infarction

Phase 1

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 765845 Are Tolerated

CompletedNCT06139341

Boehringer IngelheimHealthy

Start: 2023-07-21End: 2023-12-17Updated: 2024-01-11

A Study to Test How Well Different Doses of BI 765845 Are Tolerated by Healthy People

CompletedNCT06139315

Boehringer IngelheimHealthy

Start: 2022-06-02End: 2023-06-07Updated: 2023-11-28

Phase 2

Randomised study for double-blind, placebo-controlled evaluation of BI 765845 on top of standard of care in patients with myocardial infarction

CompletedCTIS2022-502788-39-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG, Boehringer Ingelheim Espana S.A.acute myocardial infarction

Start: 2023-11-27End: 2025-11-11Target: 194Updated: 2025-08-06

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

TerminatedNCT06139328

Boehringer IngelheimMyocardial Infarction

Start: 2023-12-05End: 2025-12-02Updated: 2026-02-04